par Benboubker, Lotfi;Dimopoulos, Meletios Athanassios;Dispenzieri, Angela;Catalano, John;Belch, Andrew AR;Cavo, Michele;Pinto, Antonello;Weisel, Katja;Ludwig, Heinz;Bahlis, Nizar NJ;Banos, Anne;Tiab, Mourad;Delforge, Michel;Cavenagh, Jamie;Geraldes, Catarina;Lee, Je-Jung;Chen, Christine;Oriol, Albert;de la Rubia, Javier;Qiu, Lugui;White, Darrell J;Binder, Daniel;Anderson, Kenneth Carl;Fermand, Jean-Paul;Moreau, Philippe;Attal, Michel;Knight, Robert;Chen, Guang;Van Oostendorp, Jason;Jacques, Christian;Ervin-Haynes, Annette;Avet-Loiseau, Herve;Hulin, Cyrille;Facon, Thierry;Meuleman, Nathalie 
; [et al.]
Référence The New England journal of medicine, 371, 10, page (906-917)
Publication Publié, 2014-09
; [et al.]Référence The New England journal of medicine, 371, 10, page (906-917)
Publication Publié, 2014-09
Article révisé par les pairs
| Résumé : | The combination melphalan-prednisone-thalidomide (MPT) is considered a standard therapy for patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two approaches. |
